Phibro Animal Health Corporation reported net sales of USD 373.9 million for the three months ended December 31, 2025, representing a 21 percent increase compared to the same period in the previous year. Adjusted EBITDA for the quarter was USD 68.06 million, up 41 percent. Net income attributable to shareholders for the six months ended December 31, 2025, was USD 36.2 million. The company’s operating income rose by USD 58.4 million, driven by higher gross profit, partially offset by increased selling, general and administrative expenses and higher costs related to Phibro Forward income growth initiatives. Interest expense, net, increased due to higher debt levels and the expiration of an interest rate swap agreement. Foreign currency losses, net, decreased, while income tax expense increased for the period. During the period, Phibro Animal Health Corporation entered into a Purchase and Sale Agreement with Zoetis Inc. in April 2024. The company continued to focus on its Phibro Forward initiative, aiming to unlock additional revenue growth and cost savings. Phibro Animal Health Corporation develops, manufactures, and markets a broad range of products for food and companion animals, as well as ingredients for personal care, industrial chemical, and chemical catalyst industries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-010317), on February 04, 2026, and is solely responsible for the information contained therein.